Best Managed Healthcare Companies To Watch For 2014

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biotechnology company Insmed (NASDAQ: INSM  ) plunged 15% today after a phase 3 trial of the company's experimental lung-infection drug Arikace disappointed Wall Street. �

So what: The trial showed that patients taking the once-daily drug Arikace had a smaller improvement in lung capacity than those treated with Novartis' (NYSE: NVS  ) twice-daily competitor TOBI, triggering plenty of investor concern over Arikace's position in the market. While Insmed said that the trial met its main objective of showing that Arikace was not statistically inferior to TOBI, the lackluster results -- it isn't exactly superior -- suggest that the drug's sales potential is limited.

Now what: Management expects to file for regulatory approval in Canada and Europe during the first half of 2014.

Top 10 Defense Stocks For 2015: Enerplus Corporation (ERF)

Enerplus Corporation, together with subsidiaries, engages in the exploration and development of crude oil and natural gas in United States and Canada. As of December 31, 2011, it had 322 MMBOE of proved plus probable reserves. The company also held a portfolio of approximately 380,000 net acres of land comprised of 75,000 net acres at Fort Berthold targeting the Bakken and Three Forks; 65,000 net acres in the Duvernay; 33,000 net acres in the Montney; 67,000 net acres in the Stacked Mannville; 30,000 net acres in the Cardium and other emerging oil plays in Canada; and 110,000 net acres in the Marcellus. In addition, it had 120 gross producing wells. The company was founded in 1986 and is headquartered in Calgary, Canada.

Advisors' Opinion:

• [By Rich Duprey]

  Canadian oil and gas producer Enerplus (NYSE: ERF  ) announced today its August monthly dividend of $0.09 Canadian per share, which is equivalent to $0.09 U.S. per share at an exchange rate of 0.9674.

• [By RichardCox]

  The first to look at is the Enerplus Resources Fund (ERF), which places most of its focus on Western Canadian properties in the mature development stage and is the largest oil and natural gas income fund in North America. For the second quarter, the company's annual production levels rose by 10%, and its diversified portfolio of high-quality growth resources puts Enerplus in a strong position to benefit from demographic trends and rising oil prices. Year-to-date, ERF has seen rallies of nearly 30% but the latest pullback in market valuations offers a new opportunity for investors to get long and gain exposure to energy markets without the added risks of companies that could be vulnerable to trade route disruptions in the Middle East (for example, in the all-important Suez Canal). With its $3.4 billion market cap and 6.4% dividend yield, Enerplus offers a stable alternative for playing energy markets and recent weakness in both commodities and the stock price itself should be viewed as a buying opportunity.

• [By RichardCox]

  The first stock choice we look at here is Enerplus Corp. (ERF), which has most of its resources invested in Western Canadian properties that are in the mature development stage. This puts the company in a solid position (as far as risk protection) for two reasons: The company is largely shielded from potential supply disruptions if Middle East conflicts cause transport blockages at the Suez Canal. Furthermore, Canada holds its position as the largest source of U.S. oil imports -- nearly doubling what is sent annually by Saudi Arabia. Yearly numbers for 2012 put Canadian oil imports at roughly 2.8 million barrels in a supportive trend that helped second-quarter earnings at Enerplus rise by 10%. The fundamental sector outlook is suggestive of additional runs higher in Enerplus, and these should begin to gain traction once the external uncertainties (political gridlock, stimulus tapering) begin to resolve themselves. The stock also comes with a 6.4% dividend yield, which will help investors weather the storm if the recent declines in oil extend further.

Best Managed Healthcare Companies To Watch For 2014: Exponent Inc.(EXPO)

Exponent, Inc., together with its subsidiaries, provides engineering and scientific consulting services worldwide. Its services include analysis of products, people, property, processes, and finances related to litigation, product recall, regulatory compliance, research, development, and design. The company offers approximately 90 different technical disciplines to solve complicated issues facing industry and government. It offers services in the areas of biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, defense technology development, ecological and biological sciences, electrical engineering and computer science, engineering management consulting, environmental and earth sciences, health sciences, human factors, industrial structures, materials and corrosion engineering, mechanical engineering, polymer science and materials chemistry, statistical and data sciences, thermal sciences, and vehicle analysis. The compa ny provides its services through a team of scientists, physicians, engineers, and business and regulatory consultants. It serves clients in automotive, aviation, chemical, construction, consumer products, energy, government, health, insurance, manufacturing, and technology sectors. The company was formerly known as The Failure Group, Inc. and changed its name to Exponent, Inc. in 1998. Exponent, Inc. was founded in 1967 and is based in Menlo Park, California.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Exponent (Nasdaq: EXPO  ) , whose recent revenue and earnings are plotted below.

Best Managed Healthcare Companies To Watch For 2014: Australia and New Zealand Banking Group Ltd (ANEWF)

Australia and New Zealand Banking Group Limited (ANZ) provides a range of banking and financial products and services to retail, small business, corporate and institutional clients. The Company conducts its operations in Australia, New Zealand and the Asia Pacific region. It also operates in a range of other countries, including the United Kingdom and the United States. The Company operates on a divisional structure with Australia, International and Institutional Banking (IIB), New Zealand, and Global Wealth and Private Banking. As of September 30, 2012, the Company had 1,337 branches and other points of representation worldwide, excluding automatic teller machines (ATMs). In September 2012, it sold its remaining shareholding in Visa Inc. In May 2013, the Company ceased to be substantial holder in respect of ING Private Equity Access Limited. Advisors' Opinion:

• [By Daniel Inman]

  Australia�� S&P/ASX 200 (AU:XJO) �rose 0.6%, as Sydney bounced back from a Monday selloff after a profit warning from QBE Insurance (AU:QBE) � (QBEIF) �surprised the market and gave broader sentiment a hit. The insurer fell another 6.4% Tuesday, but a number of banks staged a healthy recovery. National Australia Bank (AU:NAB) � (NAUBF) �rose 1.2% and Australia & New Zealand Banking Group (AU:ANZ) � (ANEWF) �added 0.9%.

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- Stocks in Australia fell early Thursday, pressured by a drop in the country's currency to a three-month low below 90 U.S. cents, and by losses on Wall Street overnight on concerns about tapering of monetary stimulus. The S&P/ASX 200 (AU:XJO) fell 28 points, or 0.5%, to 5,246, led by losses in the heavily weighted financial sector. There, shares of Westpac Banking Corp. (AU:WBC) (WEBNF) lost 1.2%, National Australia Bank Ltd. (AU:NAB) (NAUBF) declined 1%, and Australia & New Zealand Banking Group (AU:ANZ) (ANEWF) shed 0.7%. Shares of Qantas Airways Ltd. (AU:QAN) (QUBSF) sank 14% after the company warned it expects to post an underlying loss before tax of $250 million to $300 million for the six months ending Dec. 31. The carrier said trading conditions saw a marked deterioration, particularly in November with both passenger loads and yields "below the already negative trends for the year to date."

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- Australian stocks rose in early Monday trading, helped by Wall Street's gains Friday, with the S&P/ASX 200 (AU:XJO) climbing 0.8% to 5,362.40 after closing the previous session at its highest level since before the start of the 2008 financial crisis. Miners were broadly improving, as Fortescue Metals Group Ltd. (AU:FMG) (FSUMF) rose 1.3%, BHP Billiton Ltd. (AU:BHP) (BHP) added 0.9% ahead of its quarterly production report Tuesday, and Newcrest Mining Ltd. (AU:NCM) (NCMGF) also climbed 0.9% despite a loss for gold at the end of last week. Financials saw gains as well, with many analysts now tipping the U.S. Federal Reserve to maintain its current level of easing through the end of the year. Australia & New Zealand Banking Group (AU:ANZ) (ANEWF) advanced 1.1%, while Westpac Banking Corp. (AU:WBC) (WEBNF) and Macquarie Group Ltd. (AU:MQG) (MCQEF) rose 1.2% each. On the downside, shares of Qantas Airways Ltd. (AU:QAN) (QUBSF) fell 4.2% after the company warned of rough business conditions on Friday.

Best Managed Healthcare Companies To Watch For 2014: SciClone Pharmaceuticals Inc.(SCLN)

SciClone Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics for the treatment of oncology, infectious diseases, cardiovascular, urological, respiratory, and central nervous system disorders in the People?s Republic of China and internationally. Its principal product is ZADAXIN for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as a vaccine adjuvant or as a chemotherapy adjuvant for cancer patients with weakened immune systems. ZADAXIN has approval in approximately 30 countries, primarily China, the Pacific Rim, Latin America, eastern Europe, and the Middle East. The company markets and sells ZADAXIN principally through its distributors. It is also developing SCV-07, which is in Phase 2 clinical trials for the treatment of oral mucositis and hepatitis C virus. In addition, the company markets partnered products in China, including Depakine, an anti-convulsant; Tritace, an ACE inhibitor for the treatment of hypertension; Stilnox, a hypnotic for the short-term treatment of insomnia; and Aggrastat, a cardiology product. SciClone Pharmaceuticals also has commercialization rights for DC Bead, a product candidate for the treatment of advanced liver cancer in China, as well as for ondansetron RapidFilm, an oral thin film formulation of ondansetron to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery in China and Vietnam. The company was founded in 1989 and is headquartered in Foster City, California.

Advisors' Opinion:

• [By Monica Gerson]

  SciClone Pharmaceuticals (NASDAQ: SCLN) is expected to report its Q4 earnings at $0.15 per share on revenue of $38.30 million.

  Essex Rental (NASDAQ: ESSX) is projected to post a Q4 loss at $0.10 per share on revenue of $22.55 million.

• [By Eric Volkman]

  SciClone (NASDAQ: SCLN  ) has a new man leading its finance team. The company announced that it hired Wilson Cheung to be its new CFO. Cheung is a longtime executive who most recently served as chief compliance officer, Asia Pacific, at digital marketing agency Velti, following a stint as that company's CFO. Before that, he was CFO and corporate secretary at AXT (NASDAQ: AXTI  ) and served in various managerial positions in firms such as KPMG and Yahoo!

Best Managed Healthcare Companies To Watch For 2014: Spdr Nuveen Barclays Capital Short Term Municipal Bond Etf (SHM)

SPDR Nuveen Barclays Short Term Municipal Bond ETF (the Fund), formerly SPDR Nuveen Barclays Capital Short Term Municipal Bond ETF, correspond generally to the price and yield performance of the Barclays Capital Managed Money Municipal Short Term Index (the Index). The Fund uses a passive management strategy designed to track the Index. The Index tracks publicly traded municipal bonds that cover the United States dollar-denominated, short-term tax exempt bond market, including state and local general obligation bonds, revenue bonds, insured bonds and pre-refunded bonds. The Fund�� investment manager is SSgA Funds Management, Inc. Advisors' Opinion:

• [By Todd Rosenbluth]

  Fortunately, there are some short-term muni ETFs to choose from. The largest is SPDR Nuveen Barclays Short-Term Muni Bond (SHM). About 65% of the bonds inside have a AA rating, with most of the remaining ones having a AAA rating.

Best Managed Healthcare Companies To Watch For 2014: Synopsys Inc (SNPS)

Synopsys, Inc., incorporated in 1986, is engaged in providing technology solutions used to develop electronics and electronic systems. It supplies the electronic design automation (EDA) software that engineers use to design, create prototypes for and test integrated circuits, also known as chips. It also supplies software and hardware used to develop the systems that incorporate integrated circuits and the software that runs on those integrated circuits. Its intellectual property (IP) products are pre-designed circuits that engineers use as components of larger chip designs rather than redesigning those circuits themselves. It also provides technical services to support its solutions and it help its customers develop chips and electronic systems. Its products and services are organized into four groups: Core EDA (which includes the Galaxy Design Platform, the Discovery Verification Platform and its Field Programmable Gate Array (FPGA) design products); IP and System-Level Solutions; Manufacturing Solutions and Professional Services. In July 2012, it acquired Ciranova. In October 2012, it acquired EVE. On November 30, 2012, the Company acquired SpringSoft. In February 2014, Synopsys Inc completed the acquisition of Target Compiler Technologies.

On September 2, 2010, the Company acquired Virage Logic Corporation. In October 2010, the Company acquired Optical Research Associates. In September 2011, the Company acquired nSys Design Systems Private Limited (nSys). In October 2011, the Company acquired Extreme DA. In January 2012, the Company acquired ExpertIO, Inc. In February 2012, the Company acquired Magma Design Automation Inc.

Core EDA products

The Company offers a number of Core EDA products to address the process. Its Core EDA products fall into the suites, which included the Galaxy Design Platform, which includes tools to design an integrated circuit; the Discovery Verification Platform, which includes tools to verify that an integrated circuit behaves! as intended, and the FPGA design products. Its Galaxy Design Platform provides its customers with a single, integrated chip design solution, which includes individual products and incorporates common libraries and consistent timing, delay calculation and constraints throughout the design process. The platform allows designers the flexibility to integrate internally-developed and third-party tools. With this advanced functionality, common foundation and flexibility, its Galaxy Design Platform reduces design times; decrease integration costs and minimize the risks inherent in advanced, integrated circuit designs. Its products span both digital and analog/mixed-signal designs.

The products included in the Galaxy Design Platform are the IC Compiler physical design solution, Design Compiler logic synthesis product, Galaxy Custom Designer physical design solution for analog/mixed-signal designs, PrimeTime/PrimeTime SI timing analysis products, StarRC product for extraction, and the Hercules and IC Validator physical verification product family. The Lynx Design System is a production-ready chip implementation environment that combines a Galaxy-based design flow, graphical user interface (GUI)-based runtime automation, design metrics capture and reporting, and utilities that automate the configuration of pre-validated foundry data. The Lynx Design System helps customers improve their productivity and optimally deploy Synopsys tools and methodologies.

The Company�� Discovery Verification Platform is an integrated portfolio of functional, analog/mixed-signal, formal and low-power verification products. The platform includes its simulation and verification products and design-for-verification methodologies, and provides a consistent control environment to help improve the speed, breadth and accuracy of its customers��verification efforts. The Discovery Verification Platform�� components support industry standards and span both digital and analog/mixed-signal designs. The principa! l product! s included in the Discovery Verification Platform are the VCS comprehensive RTL verification solution, Formality formal verification sign-off solution, NanoSim FastSPICE circuit simulation and analysis product, high-speed interface module (HSIM) hierarchical FastSPICE circuit simulation and analysis product, HSPICE circuit simulator, and CustomSim circuit simulation solution. FPGAs are chips that can be customized or programmed to perform a specific function after they are manufactured.

Intellectual Property (IP) and System-Level Solutions

Synopsys is a provider of high-quality, silicon-proven IP solutions for system-on-chip (SoC) designs. The broad DesignWare IP portfolio includes high quality solutions for widely used interfaces such as universal serial bus (USB), PCI Express, double data rate (DDR), Ethernet, serial advanced technology attachment (SATA) and high-definition multimedia interface (HDMI). In addition, Synopsys offers analog IP for high-definition video, analog-to-digital data conversion and audio. With its recent acquisition of Virage Logic Corporation, we added embedded memories, including static random access memory (SRAMs) and non-volatile memory, logic libraries, embedded test and repair IP and configurable processor cores, to its IP portfolio.

Synopsys has a portfolio of tools, models and services for the system-level design of SoCs. Primary system-level products include Platform Architect for architectural optimization, SPW and System Studio for algorithm design, Processor Designer for custom processor design, and Synphony Model and C Compiler for High Level Synthesis. In addition to these tools for the system-level design of SoCs, its portfolio includes prototyping tools for hardware verification, software development and hardware-software integration. With FPGA-based prototyping systems (HAPS), designers can speed embedded software development by three to six months with near real runtime speeds and real world interfaces, such as its pre-t! ested Des! ignWare IP components. The HAPS hardware systems are a modular, scalable and accurate way to model a chip. Its virtual prototyping solutions enable software engineers to start SoC and application software up to twelve months before traditional methods.

Manufacturing Solutions

The Company�� Manufacturing Solutions products and technologies address this problem by introducing manufacturability and yield considerations early in the design process, thereby improving yields. Some of its Manufacturing Solutions address mask-making and yield enhancement of very small-geometry integrated circuits, as well as high-level modeling of physical effects within the integrated circuit. Its Manufacturing Solutions include the Technology-CAD (TCAD) device modeling products, Proteus OPC optical proximity correction (OPC) products, CATS mask data preparation product and yield management solutions, including odyssey and recipe manager and editor (RME), and yield explorer.

Professional Services and Training

Synopsys provides consulting and design services that address all phases of the SoC development process. These services assist Synopsys customers with new tool and methodology adoption, chip architecture and specification development, functional and low power design and verification, and physical implementation and signoff. It also provides a range of expert training and workshops on its latest tools and methodologies.

Advisors' Opinion:

• [By Anna Prior]

  Synopsys Inc.'s(SNPS) fiscal fourth-quarter profit nearly doubled on a top-line increase driven by growth in the company’s time-based license revenue. However, the company’s guidance for the current quarter came in below Wall Street expectations.

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Synopsys (Nasdaq: SNPS  ) , whose recent revenue and earnings are plotted below.

Best Managed Healthcare Companies To Watch For 2014: Conn's Inc.(CONN)

Conn?s, Inc. operates as a specialty retailer of home appliances, consumer electronics, home office equipment, lawn and garden products, mattresses, and furniture in the United States. Its home appliances products include refrigerators, freezers, washers, dryers, dishwashers, ranges, and room air conditioners; consumer electronics products consist of LED, LCD, plasma, DLP and 3-D televisions, camcorders, digital cameras, Blu-ray and DVD players, video game equipment, portable audio, MP3 players, GPS devices, and home theater products; and furniture and mattresses include living room, bedroom, and dining room furniture. The company's products also comprise lawn and garden equipment, which includes lawn mowers, lawn tractors, and handheld equipment; and home office equipment, including computers, notebooks, and computer accessories. It also offers repair service agreements and customer credit programs, including installment and revolving credit account programs, and various credit insurance products. In addition, the company sells its products online. As of January 20, 2012, it operated 70 retail locations in Texas, Louisiana, and Oklahoma. The company was founded in 1890 and is headquartered in Beaumont, Texas.

Advisors' Opinion:

• [By John Udovich]

  Small cap consumer electronics and appliance retailer�CONN'S, Inc (NASDAQ: CONN) jumped 13.04% after reporting earnings�Thursday morning, meaning its worth taking a closer look at the stock�along with the performance of�potential benchmarks or peers like mid cap Best Buy Co., Inc (NYSE: BBY) and small caps�hhgregg, Inc (NYSE: HGG) and�Aaron's, Inc (NYSE: AAN). After all, bad weather plus the weak economy or so-called recovery has weighted down consumer electronics retailers and retail in general.

• [By Roberto Pedone]

  One potential earnings short-squeeze candidate is Conn's (CONN), a specialty retailer of durable products, which is set to release numbers on Thursday before the market open. Wall Street analysts, on average, expect Conn's to report revenue of $259.74 million on earnings of 60 cents per share.

  Just recently, Piper Jaffray said that Conn's is taking steps to increase its market share, faces little competition, and should report strong second quarter earnings. The firm said Conn's is raising its market share by extending credit at relativity low rates to customers with low credit ratings. The firm has a buy rating on the stock with a $76 per share price target.

  The current short interest as a percentage of the float for Conn's is very high at 16.8%. That means that out of the 24.16 million shares in the tradable float, 4.23 million shares are sold short by the bears. This stock is a low float and high short interest situation. Any bullish earnings news could easily spark a monster short-squeeze for shares of CONN post-earnings.

  From a technical perspective, CONN is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strong for the last six months, with shares soaring higher from its low of $31.02 to its recent high of $68.73 a share. During that uptrend, shares of CONN have been consistently making higher lows and higher highs, which is bullish technical price action.

  If you're bullish on CONN, then I would wait until after its report and look for long-biased trades if this stock manages to break out to a new 52-week high above $69.30 a share with high volume. Look for volume on that move that hits near or above its three-month average action of 459,330 shares. If that breakout triggers, then CONN will set up enter new 52-week high territory, which is bullish technical price action. Some possible upside targets off that move are $75 to $80 a share.

  I would